The Use of Anticholinergics in Asthma

References

• Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51: 13–20, Suppl 7
   PubMedGoogle Scholar
• Jackson R. International trends in asthma mortality 1970 to 1985. Chest 1988; 94: 914–918
   PubMed Web of Science ®Google Scholar
• Skorodin M. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Arch Intern Med 1993; 153: 814–828
   PubMedGoogle Scholar
• Weber R. Role of anticholinergics in asthma. Ann Allergy 1990; 65: 348–350
   Google Scholar
• Gross N, Skorodin M. Anticholinergic, antimus-carinic bronchodilators. Am Rev Respir Dis 1984; 129: 856–870
   PubMed Web of Science ®Google Scholar
• Barnes P J. Neural control of airways in health and disease. Am Rev Respir Dis 1986; 134: 1289–1314
   PubMed Web of Science ®Google Scholar
• Barnes P J. The third nervous system in the lung: physiology and clinical perspectives. Thorax 1984; 39: 561–567
   PubMed Web of Science ®Google Scholar
• Lemanski R F, Casale T B, Kaliner M. The autonomic nervous system in allergic disease. Allergy, A E Kaplan. Churchill Livingstone, New York 1985; 199–209
   Google Scholar
• Skorodin M. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Arch Intern Med 1993; 153: 814–828
   PubMedGoogle Scholar
• Barnes P J. Muscarinic receptor subtypes: implications for lung disease. Thorax 1989; 44: 161–167
   PubMed Web of Science ®Google Scholar
• Barnes P J. Endogenous catecholamines and asthma. J Allergy Clin Immunol 1986; 77: 791–795
   Google Scholar
• Gross N J. The influence of anticholinergic agents on treatment for bronchitis and emphysema. Am J Med 1991; 91: 4a–11s, Suppl 4a
   Google Scholar
• Kaliner M, Shelhamer J H, Davis P B, Smith L J, Ventner J C. Autonomic nervous system and allergy. NIH conference. Ann Intern Med 1982; 96: 349–357
   PubMed Web of Science ®Google Scholar
• Marini J J, Lakshminarayan S. The effect of atropine inhalations in “irreversible” chronic bronchitis. Chest 1980; 77: 591–596
   PubMed Web of Science ®Google Scholar
• Newcomb R, Tashkin P, Hui K K, Conolly M E, Lee E, Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am Rev Respir Dis 1985; 132: 12–15
   PubMed Web of Science ®Google Scholar
• Gamain B. Bronchoconstriction following inhalation of dust or acetylcholine and its reversibility by SCH 1000 MD1. Postgrad Med 1975; 51: 102, Suppl 7
   Google Scholar
• Levin D C, Little K S, Laughlin K R, Galbraith J M. Ipratropium bromide solution in COPD augments extent and duration of FEV1 increases by albuterol up to 85 days. Chest 1993; 104: 1125, 2, Suppl
   Google Scholar
• Gross N J, Evangeline C, Skorodin M. Cholinergic bronchomotor tone in COPD. Chest 1989; 96: 984–987
   PubMed Web of Science ®Google Scholar
• Pakes G E. Ipratropium bromide: A review of its pharmacologic properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237–266
   PubMed Web of Science ®Google Scholar
• Chapman K R. Therapeutic algorithm for chronic obstructive pulmonary disease. Am J Med 1991; 97: 4A–17S, Suppl 4A
   Google Scholar
• Karpel J P. Bronchodilator response to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99: 871–876
   PubMed Web of Science ®Google Scholar
• Bleecker E R. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991; 91: 4A–24S, Suppl 4A
   Google Scholar
• Braun S R, Levy S F, Grossman J. Comparison of ipratropium bromide and albuterol in COPD: A three-country study. Am J Med 1991; 91: 4A–28S, Suppl 4A
   Google Scholar
• Chapman K R. Anticholinergic bronchodilators for adult obstructive airways disease. Am J Med 1991; 91: 4A–13S, Suppl 4A
   Google Scholar
• VanSchayck C P, Dompeling E, Van Heerwarden C L, Folgering H, Verbeek A L, Van der Hoogen H J, Van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand. Br Med J 1991; 303: 1426–1431
   Google Scholar
• Standards for the diagnosis and care of patients with COPD and asthma. American Thoracic Society (Nov 1986). Am Rev Respir Dis 1987; 136(1)225–242
   Google Scholar
• Pride N B. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years from the CIBA symposium. Thorax 1984; 39: 81–85
   Google Scholar
• Van Schayck C P, Folgering H, Harbers H, Maas K L, Van Weel C. Effects of energy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991; 46(5)355–359
   PubMed Web of Science ®Google Scholar
• Gross N J, Skorodin M S. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311: 421–425
   PubMed Web of Science ®Google Scholar
• Kaliner M. Human lung tissue and anaphylaxis. J Allergy Clin Immunol 1977; 60: 204–211
   Google Scholar
• Chapman K R. The role of anticholinergic bronchodilators in adult Asthma and chronic obstructive pulmonary disease. Lung 1990; 168: 295–303, Suppl
   Google Scholar
• Gal T J, Suratt P M, Lu J. Glycopyrrolate and atropine function: comparative effects on normal airway function. Am Rev Respir Dis 1984; 129: 871–873
   PubMedGoogle Scholar
• Mirakhur R K. Evaluation of the anticholinergic actions of glycopyrronium bromide. Br J Clin Pliarm 1978; 5: 77–84
   Google Scholar
• Slovis C M. Intravenous use of glycopyrrolate in acute respiratory distress due to bronchospastic pulmonary disease. Ann Emerg Med 1987; 16: 890–900
   Google Scholar
• Britton J, Phanley, Garrett H V, Hadfield J W, Tatters-field A E. Dose related effects of salbutamol and ipratropium bromide on airway caliber and reactivity in subjects with asthma. Thorax 1988; 43: 300–305
   PubMed Web of Science ®Google Scholar
• Ruff in RE. A comparison of the bronchodilator activity of SCH 1000 and salbutamol. J Allergy Clin Immunol 1977; 59: 136
   Google Scholar
• Pakes G E. Ipratropium bromide: A review of its pharmacologic properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237
   PubMed Web of Science ®Google Scholar
• Lefcoe N M, Toogood J H, Blennerhassett G, Baskerville J, Patterson N A. The addition of aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis. Chest 1982; 82: 300–305
   Google Scholar
• Elwood R K, Abboud R T. The short-term bronchodilator effect of fenoterol and ipratropium in asthma. J Allergy Clin Immunol 1982; 69: 467–473
   PubMed Web of Science ®Google Scholar
• Ruffin R E, McLntyre E, Crockett A J, Zielonka K, Alpers J I. Combination bronchodilator therapy in asthma. J Allergy Clin Immunol 1982; 69: 60–65
   PubMed Web of Science ®Google Scholar
• Kreisman H, Frank H, Wolkove N L, Gent M. Synergism between ipratropium and theophylline in asthma. Thorax 1981; 36: 387–391
   Google Scholar
• Grandordy B M, Thomas V, De Lauture D, Marsac J. Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium in chronic asthma. Eur Respir J 1988; 1(6)531–535
   Google Scholar
• Higgins B G, Powell R M, Cooper, Tattersfield A E. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4(4)415–420
   PubMed Web of Science ®Google Scholar
• Gross N J. The use of anticholinergics in the treatment of airways disease. Clin Chest Med 1988; 9: 591–599
   PubMed Web of Science ®Google Scholar
• Mann N P. Ipratropium bromide in children with asthma. Thorax 1982; 37: 72
   Google Scholar
• Lin M T. A clinical trial of the bronchodilator effect of SCH 1000 aerosol in asthmatic children. Ann Allergy 1978; 40: 326
   PubMedGoogle Scholar
• Rebuck A S, Gent M, Chapman K R. Anticholinergic and sympathomimetic combination therapy of asthma. J Allergy Clin Immunol 1983; 71: 317–323
   PubMed Web of Science ®Google Scholar
• Karpel J P. Anticholinergic bronchodilators in obstructive airway disease. J Assoc Acad Minor Phys 1991; 2(3)118–122
   Google Scholar
• Young G P, Freitas P. randomized comparison of atropine and metaproterenol inhalations for refractory status asthmaticus. Ann Emerg Med 1991; 20: 513–519
   Google Scholar
• Karpel J P, Appel D, Breitbart D, Fusco M J. comparison of atropine sulfate and metaproterenol sulfate in the emergency department treatment of asthma. Am Rev Respir Dis 1986; 133: 727–729
   PubMed Web of Science ®Google Scholar
• Rayner R J, Cartlidge P H, Upton C J. Salbutamol and ipratropium in acute asthma. Arch Dis Child 1987; 62: 840–841
   Google Scholar
• Ward M J, Fentem P H, Smith W H, Davies D. Ipratropium in acute asthma. Br Med J 1981; 282: 598–600
   PubMed Web of Science ®Google Scholar
• Higgins R M, Stradling J R, Lane D J. Should ipratropium be added to beta-agonists in treatment of acute severe asthma. Chest 1988; 94: 718–722
   PubMed Web of Science ®Google Scholar
• Summers Q A, Tarala R A. Nebulized ipratropium in the treatment of asthma. Chest 1990; 97: 430–434
   Google Scholar
• Rebuck A S, Chapman K. Nebulized anticholinergic and sympathomimetic treatment of asthma and COPD in the emergency room. Am J Med 1987; 82: 59–64
   PubMed Web of Science ®Google Scholar
• Bryant D H. Nebulized ipratropium bromide in the treatment of acute asthma. Chest 1985; 88: 24–29
   PubMed Web of Science ®Google Scholar
• O'Driscoll B R, Taylor R J, Horsley M G, Chambers D K. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 24: 1418–1420
   Google Scholar
• Storr J, Lenney W. Nebulized ipratropium and salbutamol in asthma. Arch Did Child 1986; 61: 602–603
   PubMed Web of Science ®Google Scholar
• Reisman J, Galdes-Sebalt M, Kazim F, Canny G, Levison H. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. J Allergy Clin Immunol 1988; 81: 16–20
   PubMedGoogle Scholar
• Beck R, Robertson C, Galdes-Sebalt M, Levison H. Combined ipratropium bromide and salbutamol by inhalation in the treatment of severe acute asthma. J Pediatr 1985; 107: 605
   PubMed Web of Science ®Google Scholar
• Schuh S. Efficacy of frequently nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995; 126(4)639–645
   PubMedGoogle Scholar
• Schroeckenstein D C, Bush R K, Chervinsky P, Busse W W. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol 1988; 82: 115–119
   PubMed Web of Science ®Google Scholar
• Walker F B, Kaiser D L, Kowal M B, Suratt P M. Prolonged effect of inhaled glycopyrrolate in asthma. Chest 1987; 91: 49–51
   PubMed Web of Science ®Google Scholar
• Gilman M J, Meyer L, Carter J, Slovis C. Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma. Chest 1990; 98: 1095–1098
   PubMed Web of Science ®Google Scholar
• Cydulka R K, Emerman C L. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. Ann Emerg Med 1994; 23: 270–274
   PubMed Web of Science ®Google Scholar
• Lulling J, Delwiche J P, Prignot J. Early bronchodilating effect of oxitropium bromide in comparison with ipratropium bromide. Respiration 1981; 42: 188–192
   PubMed Web of Science ®Google Scholar
• Peel E T, Anderson G, Cheong B, Broderick N L. comparison of oxitropium and ipratropium bromide in asthma. Eur J Respir Dis 1984; 65: 106–108
   PubMedGoogle Scholar
• Nishi K, Fujimura M, Myou S, Ooka T, Sakamoto S, Saitou M, Kasahara K, Matsuda T. Comparison of the bronchodilator activities of oxitropium, fenoterol, and their combination in patients with COPD and asthma. Clin Autonom Res 1993; 3: 41–44
   PubMedGoogle Scholar
• Frith P A, Jenner B, Dangerfield R, Atkinson J, Drennan C. Dose-response and time-response study of a new anticholinergic bronchodilator drug. Chest 1986; 89: 249–253
   Google Scholar
• Nolle D. Double-blind cross-over comparison between a beta-adrenergic agent and a new anticholinergic agent by metered dose inhaler. Respiration 1978; 36: 32–38
   Google Scholar
• Bryant D H, Rogers P. Oxitropium bromide: An acute dose response study of a new anticholinergic drug in combination with fenoterol in asthma and chronic bronchitis. Pulmon Pharmacol 1990; 3: 55–58
   Google Scholar
• Barnes P J. Orcadian variation in airway function. Am J Med 1985; 79: 5–9, Suppl 6A
   PubMed Web of Science ®Google Scholar
• Hetzel M R, Clark T J, Houston K. Physiologic patterns in early morning asthma. Thorax 1977; 32: 418–423
   PubMedGoogle Scholar
• Morrison J F, Pearson S B, Dean H G. Parasympathetic nervous system in nocturnal asthma. Br Med J 1988; 296: 1426–1429
   Google Scholar
• Sanjiv S, Mohiuddin A A, Vichyanond P, Nelson H S. random double-blind trial of the combination of nebulized atropine methylnitrate and albuterol in nocturnal asthma. Ann Allergy 1990; 65: 384–388
   Google Scholar
• Cox I D. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med J 1984; 60: 526–528
   PubMed Web of Science ®Google Scholar
• Coe C I. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest 1986; 90: 485–488
   PubMed Web of Science ®Google Scholar
• McFadden E R. An analysis of exercise as a stimulus for the production of airway obstruction. Lung 1981; 159: 3–11
   PubMed Web of Science ®Google Scholar
• Finnerty J P. The con tribution of histamine release and vagal reflexes, alone and in combination, to exercise-induced asthma. Eur Respir J 1993; 6: 1132–1137
   Google Scholar
• Johnson B E, Suratt P M, Gal T J, Wilhoit S C. Effect of inhaled glycopyrrolate and atropine in asthma. Chest 1984; 85: 325–328
   PubMed Web of Science ®Google Scholar
• Pakes G E, Brogden R N, Heel R C, Speight T M, Avery G S. Ipratropium bromide: A review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237–266
   PubMed Web of Science ®Google Scholar
• Smith C M, Anderson S D, Scale J P. The duration of action of the combination of fenoterol and ipratropium in protecting against asthma provoked by hyperpnea. Chest 1988; 94(4)709–717
   Google Scholar
• Grieco M H. Mechanism of bronchoconstriction due to beta-adrenergic blockade. J Allergy Clin Immunol 1971; 48: 143–152
   Google Scholar
• Shoene R B. Timolol-induced bronchoconstriction in asthmatic bronchitis. JAMA 1981; 245: 1460
   Google Scholar
• Toogood J H. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81: 1–5
   PubMed Web of Science ®Google Scholar
• Ind P W, Barnes P J, Durham S R, Kay A B. Propanolol-induced bronchoconstriction in asthma: Beta-receptor blockade and mediator release. Am Rev Respir Dis 1984; 129: 10, Suppl A
   Google Scholar
• Ind P W, Dixon C M, Fuller R W, Barnes P J. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Thorax 1986; 41: 718, abstract
   Google Scholar
• Ind P W, Dixon C M, Fuller R W, Barnes P J. Anticholinergic blockade of propanolol induced bronchoconstriction. Thorax 1986; 47: 718, abstract
   Google Scholar
• McFadden E R. The mechanisms of action of suggestion of acute asthma attacks. Psychosom Med 1969; 31: 134–143
   PubMed Web of Science ®Google Scholar
• Neild J E, Cameron I R. Bronchoconstriction in response to suggestion: Its prevention by an inhaled anticholinergic agent. Br Med J 1985; 290: 674
   PubMed Web of Science ®Google Scholar
• Hurd S S, Lenfant C. The National Heart, Lung and Blood Institute asthma program. Chest 1992; 101: 359S, Suppl
   Google Scholar
• National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. National, Heart, Lung, and Blood Institute. Bethesda, MD 1991, DHHS publication no. (NIH) 91–3042
   Google Scholar
• Med Lett 1939; 37: 1–4, 1995
   Google Scholar
• Chapman K R. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. Lung 1990; 168: 295–303, Suppl
   Google Scholar
• Cohen D. Management of acute asthmatic attacks in children. South African Childhood Asthma Working Group. S Afri Med J 1993; 53: 286–288
   Google Scholar
• Lulich K M. Ipratropium, sodium cromoglycate and antihistamines. T Med J Aust 1995; 162: 157–159
   Google Scholar
• Anderson S D. Drugs and the control of exercise-induced asthma. Eur Respir J 1993; 6: 1090–1092
   Google Scholar
• Ullah M I, Newman G B, Saunders K B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523–529
   PubMed Web of Science ®Google Scholar
• Newhouse M T, Dolovich M. Aerosol therapy of reversible airflow obstruction. Concepts and clinical applications. Chest 1987; 91: 59S–64S, Suppl
   Google Scholar